Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
time decrease » time increased (Expand Search), sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
increase decrease » increased release (Expand Search), increased crash (Expand Search)
time decrease » time increased (Expand Search), sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
-
2621
Comparative costs of HCVST and PL-HCVT models in sensitivity analysis (in US$).
Published 2025Subjects: -
2622
HCV positivity rate by key population group opting for HCVST and standard HCVT.
Published 2025Subjects: -
2623
-
2624
-
2625
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2626
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2627
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
-
2628
-
2629
-
2630
-
2631
-
2632
-
2633
-
2634
-
2635
-
2636
-
2637
-
2638
-
2639
-
2640